ArticleJournal of clinical medicine2023
Incidence of Gastric Neoplasms Arising from Autoimmune Metaplastic Atrophic Gastritis: A Systematic Review and Case Reports.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06881511 (Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk of Gastric Neoplasms in Patients with Autoimmune Gastritis: A Systematic Review and Meta-Analysis.Gut and liver · 2026Pooled it
- Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom.British journal of cancer · 2024Pooled it
- The origins and progression of pyloric metaplasia following gastric mucosal injury.Physiological reviews · 2026Review
- Cost-effectiveness of liquid biopsy screening for gastric cancer in the United States.JNCI cancer spectrum · 2026Article
- Autoimmune gastritis: emerging insights and clinical management.Nature reviews. Gastroenterology & hepatology · 2026Review
- Serum pepsinogen Ⅰ and the pepsinogen Ⅰ/Ⅱ ratio as a non-invasive predictive marker for autoimmune metaplastic atrophic gastritis.Journal of translational autoimmunity · 2026Article
- Spurious Elevations of Chromogranin A in the Setting of Autoimmune Metaplastic Atrophic Gastritis.Cureus · 2026Article
- Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.Frontiers in endocrinology · 2026Article
- Pediatric autoimmune gastritis: An international, multicentric study.Journal of pediatric gastroenterology and nutrition · 2025Article
- Review
- Autoimmune Gastritis: Unveiling the Mystery.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Gastric cancer in patients withWorld journal of gastrointestinal oncology · 2025Article
- Unveiling Cancer-Related Metaplastic Cells in Both Helicobacter pylori Infection and Autoimmune Gastritis.Gastroenterology · 2025Article
- Immunological and clinical overlap between autoimmune gastritis and autoimmune liver diseases: a prospective cohort study.Frontiers in immunology · 2025Article
- Autoimmune gastritis studies and gastric cancer: True renaissance or bibliometric illusion.World journal of gastroenterology · 2024Review
- Autoimmune Gastritis and Hypochlorhydria: Known Concepts from a New Perspective.International journal of molecular sciences · 2024Review
- The TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain.BMC cancer · 2024Article
- Article
- Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis.World journal of gastrointestinal oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Autoimmune metaplastic atrophic gastritis (AMAG) is associated with an increased risk of gastric neoplasms. This study aimed to systematically analyze the incidence rate of gastric cancer (GC), low-grade dysplasia (LGD) and type-1 gastric neuroendocrine tumor (gNETs) development in AMAG adults. Studies on AMAG patients reporting the incidence of gastric neoplasms was identified through a systematic search in PUBMED and EMBASE. Study quality was assessed using the Joanna Briggs Institute quality assessment tool. Incidence rates of GC, LGD and type-1 gNETs were examined by meta-analysis. Thirteen studies met eligibility criteria. Incidence rate of gastric cancer calculated from the pooled data was 0.14% per person-year in both single-center studies and national registration studies. Meta-analysis showed a relative risk of 11.05 (95% CI: 6.39-19.11) for gastric cancer development in AMAG patients. The calculated pooled gastric LGD and type-1 gNETs incidence rates were 0.52% and 0.83% per person-year, respectively. As for experience from our center, we presented three distinctive cases of gastric neoplasm arising from the background of AMAG. This study underscores the potential for malignant transformation of precancerous lesions and reiterates the importance of careful esophagogastroduodenoscopy screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.